|
ICORG Publications
Peer Reviewed Papers
In Press:
 |
Sinead M. Brennan, M.D.Pierre Thirion, M.D. Steve Buckney, Carmel O. Shea, John Armstrong, M.D
Factors influencing conformity index in radiotherapy for non-small cell lung cancer (ICORG 99-01) Medical Dosimetry, 2009, In Press, Uncorrected Proof, Available online 7 February 2009. Click to download |
Published:
|
Carmen J. Allegra, Greg Yothers, Michael J. O'Connell, Saima Sharif, Linda H. Colangelo, Samia H. Lopa, Nicholas J. Petrelli, Richard M. Goldberg, James N. Atkins, Thomas E. Seay, Louis Fehrenbacher, Seamus O'Reilly, Luis Chu, Catherine A. Azar, Norman Wolmark Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer (ICORG 05-02) Journal of Clinical Oncology, Vol 27, No 20 (July 10), 2009: pp. 3385-3390. Click to download |
|
Jacqueline Ryan, Fiona Quinn, Armelle Meunier, Ludmila Boublikova, Mireille Crampe, Prerna Tewari, Aengus O'Marcaigh, Ray Stallings, Michael Neat, Ann O'Meara, Fin Breatnach, Shaun McCann, Paul Browne, Owen Smith, Mark Lawler.
Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches British Journal of Haematology, 2009; 144 (1); 107-115.
Click to download |
|
Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjold, Istvan Lang, Raimud Jakesz, Daniel Vordiof, Jorge Gutierrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D Gelber, Aron Goldhirsch, Monica Castigilone-Gertsch, Martine picart-Gebhart. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: breast international group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133. Click to download |
|
Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M,Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M; On behalf of the BIG 02-98 Collaborative Group. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup phase III BIG 02-98 trial (ICORG 98-01). Ann Oncol. 2008 Jun 18. Click to download |
|
Charles E. Geyer, M.D., John Forster,
M.Sc., Deborah Lindquist, M.D., Stephen Chan, M.D., C. Gilles
Romieu, M.D., Tadeusz Pienkowski, M.D., Ph.D., Agnieszka
Jagiello-Gruszfeld, M.D., John Crown, M.D., Arlene Chan,
M.D., Bella Kaufman, M.D., Dimosthenis Skarlos, M.D., Mario
Campone, M.D., Neville Davidson, M.D., Mark Berger, M.D.,
Cristina Oliva, M.D., Stephen D. Rubin, M.D., Steven Stein,
M.D., and David Cameron, M.D. Lapatinib plus Capecitabine
for HER 2- Positive Advanced Breast Cancer. N ENGL J
MED, 2006; 355 (26): 2733-2743. Click
to download. |
|
Leonard, R.C.F; Lind, M; Twelves, C; Coleman, R; van Belle, S; Wilson, C; Ledermann, J; Kennedy, I; Barrett-Lee, P; Perren, T; Verrill, M; Cameron, D; Foster, E; Yellowlees, A; Crown, J. Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial (ICORG 97-02). JNCI, 2004. Vol. 96, No. 14, 1076-1083. Click to download |
Oral Presentations
Abstracts:
|
P Thirion, S Brennan, D Fitzpatrick, J Armstrong, M Dunne, C O’Shea, A McElroy. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy (ICORG 99-09). 10th biennial ESTRO conference, Maastricht, The Netherlands 30th August – 3rd September, 2009. S48 Symposium. Click to download |
|
M. Martin, S. Hurvitz, J. Kennedy, J. Forbes, H. Roché, T. Pinter, W. Eiermann, M. Buyse, M. Rupin, J. Mackey. CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC) (ICORG 06-06). European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 259. Abstract: 5001. Joint ECCO 15th-34th ESMO Multidiciplinary Congress Berlin, 20-24 September, 2009. Click to download |
|
R. Adams, R. Wilson, M.T. Seymour, A.M. Meade, A. Madi, J. Cassidy, D. Fisher, S. Kenny, R. Kaplan, T.S. Maughan. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) (ICORG 06-07). European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 10. Abstract 15LBA. Joint ECCO 15th-34th ESMO Multidiciplinary Congress Berlin, 20-24 September, 2009. Click to download |
|
T. Maughan, R.A. Adams, C.G. Smith, M.T. Seymour, R. Wilson, A.M. Meade, D. Fisher, A. Madi, J. Cheadle, R. Kaplan. Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) (ICORG 06-07). European Journal of Cancer Supplements, Vol. 7, No 3, September 2009, Page 4. Abstract 6LBA. Joint ECCO 15th-34th ESMO Multidiciplinary Congress Berlin, 20-24 September, 2009. Click to download |
|
O’Reilly S. A Phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and oxaliplatin (mFOLFOX6) with and without bevacizumab for the treatment of patients with resected stages II and III carcinoma of the colon (ICORG 05-02) NSABP C08. A late breaking abstract to be included in the plenary session at 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 2009. Click to download |
|
Morris T.C.M.1, Kettle P.J.1 Drake, M.1, Brunton A.2, Cook G.3, Leahy, M4, O’Dwyer M.5, Murray, M 5, Enright H.6, McCloy, M.7 O’Gorman, P 7 Yong, K.8O’Shea T.9, Popat R.10, Oakervee, H.10 Cavenagh J. The PAD (Ireland) study for patients with refractory and relapsed myeloma – an update. 12th International Myleoma Workshop, 26th February- 1st March, 2009.Click to download |
|
Eiermann W, Pienkowski T, Crown J, Chap L, Pawlicki M, Martin M, Saleh M, Sehdev S, Provencher L, Von Minckwitz G, Semiglazov V, Slamon D, Tabah-Fisch I, Buyse M, Riva A, Taupin H, Sauter G, Mackey J, on Behalf of the BCIRG005 Investigators.
BCIRG 05 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC T) in women with Her-2/neu negative axillary lymph node positive early breast cancer. 31st Annual San Antonio Breast Cancer Symposium, December 10-14, 2008. Click to download |
|
C. J. Poole, L. Hiller, H. C. Howard, J. A. Dunn, P. Canney, A. M. Wardley, M. J. Kennedy, R. E. Coleman, R. C. Leonard, H. M. Earl, and tAnGo trial collaborators
tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2008 26: 506.
Click to download |
|
S. M.
Brennan, D. Fitzpatrick, J.
Armstrong, A. McElroy, M. Dunne, C. O Shea, P. Thirion; St Luke's Hospital,
Rathgar, Dublin, Ireland; St Luke's Hospital, Rathgar, Dublin, Ireland. Hypofractionated
accelerated high dose radiotherapy (RT) in non small cell lung cancer (NSCLC). 08-AB-34609-ASCOAM. Click to download |
|
Mullaney L, Cleary LA, O’Shea E, Armstrong J, O Hara T, O’Neill L, Thirion P. Interim results from a randomised trial comparing the bladder volume consistency achieved with two bladder-filling protocols in prostate conformal radiotherapy (ICORG 05-04). Radiother Oncol 2008; 88 (Suppl 2): S176 (Oral presentation, abstract 539) ESTRO 2008 Meeting. Click to download |
|
M. Pegram, J. Forbes, T. Pienkowski,
V. Valero, W. Eiermann, G. Von Minckwitz, M. Martin, J. Crown,
H. Taupin, D. Slamon on behalf of the BCIRG007 investigators. BCIRG 007: First overall survival analysis of randomized
phase III trial of trastuzumab plus docetaxel with or without
carboplatin as first line therapy in HER2 amplified metastatic
breast cancer (MBC). Journal of Clinical Oncology,
2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol
25, No 18S (June 20 Supplement), 2007: LBA1008. Click to download. |
|
N. J. Robert, W. Eiermann, T. Pienkowski, J. Crown, M. Martin, M. Pawlicki, A. Chan, V. Bee, D. Slamon,
H. Au on behalf of the BCIRG 006 Investigators. BCIRG 006:Docetaxel and trastuzumab-based regimens improve DFS and
OS over AC-T in node positive and high risk node negative
HER2 positive early breast cancer patients: Quality of life
(QOL) at 36 months follow-up. Journal of Clinical Oncology,
2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol
25, No 18S (June 20 Supplement), 2007: 19647. Click to download. |
|
J. F. Forbes, T. Pienkowski, V. Valero,
W. Eiermann, G. Von Minckwitz, M. Martin, M. Smylie, J. M.
Crown, Dr, N. Noel, M. Pegram On behalf of the BCIRG007 investigators.
BCIRG 007: Randomized phase III trial of trastuzumab plus
docetaxel with or without carboplatin first line in HER2
positive metastatic breast cancer (MBC). Journal of Clinical
Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting
Edition). Vol 24, No 18S (June 20 Supplement), 2006: LBA516. Click to download. |
|
J. P. Crown et al., Docetaxel (T)
given concurrently with or sequentially to anthracycline-based
(A) adjuvant therapy (adjRx) for patients (pts) with node-positive
(N+) breast cancer (BrCa), in comparison with non-T adjRx:
First results of the BIG 2–98 Trial at 5 years median
follow-up (MFU). Journal of Clinical Oncology, 2006
ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol
24, No 18S (June 20 Supplement), 2006: LBA519. Click to download. |
|
Slamon. D. et al., Phase III randomized
trial comparing doxorubicin and cyclophosphamide followed
by docetaxel (AC T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (AC TH) with docetaxel,
carboplatin and trastuzumab (TCH) in HER2 positive early
breast cancer patients: BCIRG 006 study. 28th Annual
San Antonio Breast Cancer Symposium December 8-11 2005. Click to download. |
|
P. Thirion, C. Kelly, C. O' Shea, C. Collins, O. Holmberg, M. Michael, M. Pomeroy, D. Hollywood, C. Faul, J. Armstrong. Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3-D radiation for non small cell lung carcinoma. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 7233. Click to download |
|
J. Armstrong, J.Taylor, P.Thirion, P.Henry, D. Hollywood, L.O’Neill, S. Cosgrove, C. Horan, M. Stevenson, M.Butler. Preliminary results of a randomized trial comparing short vs. protracted neoadjuvant hormonal therapy (NHT) prior to radiation therapy (RT) of localized prostate cancer (ICORG 97-01). ESTRO 171 Oral Presentation. Click to download |
Posters
Abstracts:
|
R. A. O'Connor, M. J. Kennedy, S. R. McDermott, D. Tryfanopoulos, C. McCreery, D.Collins, O. Martynyuk, R. Gethins, B. Moulton, J. Crown; Phase I evaluation of lapatinib (L) and epirubicin (E) in patients (pts) with anthracycline (anth)-naïve metastatic breast cancer (MBC) (ICORG 06-30) Poster abstract 09-AB-34655-ASCO 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 2009. Click to download |
|
Gunn O'Connor S, McCloy R, McCafferty B, Rangaswamy G, Small C, Keane G, Collins C, Clayton-Lea A, O'Shea E, Thirion P: Prospective evaluation of PET-CT scan in patients with non-operable or non-resectable NSCLC treated by radical 3-dimensional conformal radiation therapy (ICORG 06-35) Radiother Oncol 2008; 88 (suppl 2): [abst 1109] [poster presentation] Click to download |
|
S. M. Brennan, D. Fitzpatrick, J. Armstrong, A. McElroy, M. Dunne, C. O Shea, P. Thirion. Hypofractionated accelerated high dose radiotherapy (RT) in non small cell lung cancer (NSCLC) (ICORG 99-09). Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 26, No 18S (May 20 Supplement), 2008: Abstract 7527. Click to download |
|
S. M. Brennan, D. Fitzpatrick, J. Armstrong, A. McElroy, M. Dunne, C. O Shea, P. Thirion. The effect of Hypofractionated accelerated radiotherapy (RT) on pulmonary function in non small cell lung cancer NSCLC (ICORG 99-09). 6th BTOG meeting, January 2008. Click to download |
|
Flemming C, Kelly C, Thirion P, Fitzpatrick K, Armstrong J. A method using equivalent uniform dose for the prediction of late organ-at-risk toxicity following radiotherapy of the prostate (ICORG 97-01). Radiother Oncol 2007; 84(Suppl 1) [Poster, abstract 344]. Click to download |
|
Armstrong J, Fitzpatrick D, Taylor J, Thirion P. Results of a randomised trial comparing short vs. protracted neoadjuvant hormonal therapy prior to radiation therapy of localised prostate cancer, (ICORG 97-01). Eur J Cancer 2007; 5(4):290 [Poster, abstract 4038]. Click to download |
|
T.C.M. Morris, P.J. Kettle, M. Drake, A. Brunton, G. Cook, M. Leahy, M O’Dwyer, H. Enright, T. O’Shea, R. Popat, H. Oakervee, J. Cavenagh. PAD given at relapse is more effective than VAD given as induction therapy- Results of a Phase II study (ICORG 05-01). Blood (ASH Annual Meeting Abstracts) Nov 2007 110: Abstract 2724. Click to download |
|
|
|
